Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (790)	4/12/1999 2:55:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1073

>> though you must realize that this is quite a complex issue << I'm certainly lost. (big grin) But, I'll come up to speed with the info that you've imparted. Thanks!

To: Biotech Jim who wrote (790)	4/12/1999 3:03:00 PM
From: Biomaven	Respond to of 1073

BJ, All I can offer is a slide No. 21 of the ML presentation at the SEPR web site. corporate-ir.net It shows that if you go to the + antiomer of desmethylsibutramine, you lose the hypertension/anticholinergic side effects of the parent. It shows activity for "SSRI, NERI, DRI, Beta3." I assume these are serotonin, norepinephrine and dopamine reuptake inhibitors respectively, and some sort of Beta3 adrenergic activity. (Note that the racemic compound is not shown as having Beta3 activity for some reason). Given that sibutramine seems to have a dose dependent weight loss effect, and is essentially dose limited by side-effects, it is plausible that the SEPR version could be quite a bit more effective. Anyhow an antidepressant with a significant weight loss side effect would create a sensation. <G> Peter